Recent News
‘Breaking the mold with RNA—a “RNAissance” of life science’ – npj Genomic Medicine
Apr 2024
Beacon maps over 2300 lung cancer biomarkers in new global database – PBI Forum
Feb 2024
New day for antibody-drug conjugates – Chemical & Engineering News
May 2022
What makes a good antibody–drug conjugate? – Martin De Cecco, Daniel N. Galbraith & Lisa L. McDermottt
Feb 2021
Beacon Targeted Therapies announces the launch of Beacon Oncolytic Viruses
Jul 2020
Cell Therapy 2.0
Jul 2020
Overcoming Challenges in the Development of Anticancer ADCs
Jun 2020
Immuno-oncology cell therapies: commercial considerations and strategies for the new decade
Jun 2020Beacon Targeted Therapies announces the launch of Beacon Gene Therapy
May 2020
Frontiers in Oncology – Perspective: Designing T-Cell Engagers With Better Therapeutic Windows
Apr 2020Hot Topics at CAR-TCR 2020
Apr 2020
Assessment of Clinical Activity of PD-1 Checkpoint Inhibitor Combination Therapies Reported in Clinical Trials
Feb 2020
TCR Therapies Summit 2020 Magazine
Feb 2020
Drug developers take fresh aim at ‘guided-missile’ cancer drugs
Jan 2020
CAR-TCR Europe Summit 2020 Magazine
Jan 2020
World ADC London 2020 Magazine
Jan 2020
Innate Killer Summit 2020 Magazine
Jan 2020
From Mylotarg to Polivy: Ebbs and flows, successes and woes of ADCs
Nov 2019Trends & Forecasts – Tenacious ADCs
Nov 2019
World ADC San Diego Magazine 2019
Sep 2019
Biomarkers for Checkpoint Inhibition and Their Clinical Utility – Timothy James Fabisiak, B.A.
Jul 2019
Bispecific antibodies: a mechanistic review of the pipeline Aran F. Labrijn, Maarten L. Janmaat, Janice M. Reichert & Paul W. H. I. Parren
Jun 2019
Beacon Targeted Therapies Launches Beacon Adoptive Cell
May 2019
The Evolving Shape of the ADC Market: The Widening Application of ADCs and Manufacturing Improvements Meeting Demand – Charlie Johnson, CEO of ADC Bio, adcbio.com
Mar 2019